Immune Reconstitution and Long-Term Immunologic Changes Following Transitionfrom anti-CD20 Therapy
Study of OCR/RTX vs. Diroximel for Patients with Relapsing-Remitting Multiple Sclerosis (RRMS) or Clinically Isolated Syndrome (CIS)
Sponsor: Biogen
Enrolling: Male and Female Patients
IRB Number: AAAU2756
Contact: Kaho Onomichi: 212-305-2434 /
Additional Study Information: The purpose of this study is to evaluate the differences between immune profiles of individuals remaining on Ocrelizumab/Rituximab versus those transitioning to diroximel fumarate at two years. Baseline visits for subjects transitioning to diroximel fumarate (DRF) will take place 6 months after last Ocrelizumab (OCR) or Rituximab (RTX) dose, prior to beginning DRF. Baseline visit for individuals remaining on OCR/RTX will take place prior to OCR/RTX dose. Visits will occur every 6 months for 24 months (total of 5 study visits). Visits will include blood draw as well as clinical assessments.
Rebecca Straus Farber, MD
Do You Qualify?
Are you between the ages of 18-60? Yes No
Have you been diagnosed with Relapsing-Remitting Multiple Sclerosis (RRMS) or Clinically Isolated Syndrome (CIS)? Yes No
Have you been on Ocrelizumab/Ocrevus (OCR) or Rituximab/Rituxan (RTX) for at least 2 years? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Kaho Onomichi